# Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain

> **NCT05598736** · NA · UNKNOWN · sponsor: **Otivio AS** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Sclerosis
- Spasticity, Muscle
- Pain

## Interventions

- **DEVICE:** FlowOx 2.0

## Key facts

- **NCT ID:** NCT05598736
- **Lead sponsor:** Otivio AS
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-04
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598736, "Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05598736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*